Weill Medical College of Cornell University: Myelodysplastic Syndromes trials

The registry lists 11 Myelodysplastic Syndromes studies with Weill Medical College of Cornell University as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 4Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk LeukemiaTerminatedNCT02508324Phase 2Results posted
• Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CRCompletedNCT02497404Phase 2Results posted
• Study of Clinical Efficacy and Safety of Tosedostat in MDSCompletedNCT02452346Phase 2Results posted
• Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based TherapyCompletedNCT01980056Phase 1/2Results posted
• Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic MalignanciesTerminatedNCT01745913Phase 2Results posted
• Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic SyndromesTerminatedNCT00840827Phase 2Results posted
• CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
• A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
• MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell TransfusionsCompletedNCT00749372Not applicable
• Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AMLCompletedNCT00195104Phase 1/2
• Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2